Overview and Scope
Muscarinic acetylcholine receptors (mAChRs) are a class of G protein-coupled receptors (GPCRs) that are activated by the neurotransmitter acetylcholine. They are widely distributed throughout the body and play a crucial role in various physiological processes, particularly in the central and peripheral nervous systems.
Sizing and Forecast
The muscarinic acetylcholine receptor market size has grown steadily in recent years. It will grow from $1.72 billion in 2023 to $1.8 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to neurological disorders treatment, cardiovascular disorders management, ophthalmic disorders therapies, respiratory conditions treatment, gastrointestinal disorders..
The muscarinic acetylcholine receptor market size is expected to see steady growth in the next few years. It will grow to $2.19 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to advancements in neuropharmacology, increasing cardiovascular disease cases, innovations in ophthalmic therapeutics, emerging respiratory therapies, expanding gastrointestinal drug pipeline.. Major trends in the forecast period include utilization in ophthalmic conditions, strategic partnerships for drug discovery, development of tissue-selective agents, potential in gastrointestinal disorders, focus on personalized treatment approaches..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/muscarinic-acetylcholine-receptor-global-market-report
Segmentation & Regional Insights
The muscarinic acetylcholine receptor market covered in this report is segmented –
1) By Type: M1, M4, M5, Other Types
2) By Distribution Channel: Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Specialty Centers
3) By Application: Chronic Obstructive Pulmonary Disease, Attention Deficit Hyperactivity Disorder, Alzheimer’s Disease, Memory Impairment, Psychiatric Disorders, Other Applications
North America was the largest region in the muscarinic acetylcholine receptor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global muscarinic acetylcholine receptor market during the forecast period. The regions covered in the muscarinic acetylcholine receptor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10861&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of neurological disorders is expected to propel the growth of the muscarinic acetylcholine receptor market going forward. Neurological disorders are medical conditions that affect the nervous system, including the brain, spinal cord, and peripheral nerves. Muscarinic acetylcholine receptors (mAChR) are critical in regulating complex behaviors, including cognition, locomotion, and reward, making them suitable therapeutic targets for treating various neurological illnesses. For instance, in September 2021, according to evidence submitted by The Neurological Alliance (CBP0062), the number of persons waiting to begin neurology therapy in June 2021 increased from 134,245 in May 2021 to 140,482. Additionally, in January 2022, according to the American Heart Association, a US-based nonprofit organization that supports medical research, the number of persons affected by Alzheimer’s disease and associated dementias in the United States is expected to rise to 9.3 million by 2060. Therefore, the increasing prevalence of neurological disorders is driving the growth of the muscarinic acetylcholine receptor market.
Key Industry Players
Major companies operating in the muscarinic acetylcholine receptor market report are Heptares Therapeutics Ltd., Sumitomo Dainippon Pharma Co. Ltd., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc., AstraZeneca PLC, Karuna Pharmaceuticals Inc., Anven AlzDx Inc., Merck & Co Inc., Elsevier BV, Eurofins Discover X Corporation, Merck KGaA, Novus Biologicals LLC, Eli Lilly and Co., Novatein Biosciences Inc., Alomone Labs Ltd., GlaxoSmithKline PLC, SK Bioscience Co., Johnson & Johnson, Pfizer Inc., Novartis AG, AbbVie Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Eisai Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sanofi SA, Sun Pharmaceutical Industries Ltd.
The muscarinic acetylcholine receptor market report table of contents includes:
1. Executive Summary
2. Muscarinic Acetylcholine Market Characteristics
3. Muscarinic Acetylcholine Market Trends And Strategies
4. Muscarinic Acetylcholine Market – Macro Economic Scenario
5. Global Muscarinic Acetylcholine Market Size and Growth
.
.
.
31. Global Muscarinic Acetylcholine Market Competitive Benchmarking
32. Global Muscarinic Acetylcholine Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Muscarinic Acetylcholine Market
34. Muscarinic Acetylcholine Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
